- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing the Payer/Provider Relationship for a Successful Annual Enrollment Period, Part 3
Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.
In the latest Matters in Managed Care webinar, experts discussed current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries. They discussed the health system, provider, and payer perspectives.
Steve Evans, MD, vice president for quality and utilization management, Intermountain Healthcare, moderated the panel with:
- Judith Ford, MD, medical director, Intermountain Healthcare
- Othella Ann Jurani-Suarez, MD, medical director, Intermountain Healthcare
- Kristine Gates, government program sales director, SelectHealth
- Matt Maher, senior sales manager, Humana
- Sherry Stanislaw, general manager, officer, SCAN Health Plan
In segment 3, they discussed patient costs and health outcomes.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
Managed Care Reflections: A Q&A With John Michael O’Brien, PharmD, MPH
May 5th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
Read More
